Human Leukocyte immunoglobulin-like receptor subfamily A member 3(LILRA3) ELISA kit

Instructions
Code CSB-EL012935HU
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name leukocyte immunoglobulin-like receptor, subfamily A (without TM domain), member 3
Alternative Names CD 85E ELISA Kit; CD85 antigen-like family member E ELISA Kit; CD85e ELISA Kit; CD85e antigen ELISA Kit; e3 ELISA Kit; HM 31 ELISA Kit; HM 43 ELISA Kit; HM31 ELISA Kit; HM43 ELISA Kit; ILT 6 ELISA Kit; ILT-6 ELISA Kit; ILT6 ELISA Kit; Immunoglobulin like transcript 6 ELISA Kit; Immunoglobulin-like transcript 6 ELISA Kit; Leucocyte immunoglobulin like receptor ELISA Kit; Leukocyte immunoglobulin like receptor 4 ELISA Kit; Leukocyte immunoglobulin like receptor A3 ELISA Kit; Leukocyte immunoglobulin like receptor subfamily A (without TM domain) member 3 ELISA Kit; Leukocyte immunoglobulin like receptor subfamily A member 3 ELISA Kit; Leukocyte immunoglobulin-like receptor 4 ELISA Kit; Leukocyte immunoglobulin-like receptor subfamily A member 3 ELISA Kit; LILRA 3 ELISA Kit; LILRA3 ELISA Kit; LIR 4 ELISA Kit; LIR-4 ELISA Kit; LIR4 ELISA Kit; LIRA3_HUMAN ELISA Kit; Monocyte inhibitory receptor HM43/HM31 ELISA Kit
Abbreviation LILRA3
Uniprot No. Q8N6C8
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates
Detection Range 0.156 ng/mL-10 ng/mL
Sensitivity 0.039 ng/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Immunology
Assay Principle quantitative
Measurement Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human LILRA3 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
 SampleSerum(n=4)
1:1Average %87
Range %80-94
1:2Average %95
Range %91-103
1:4Average %102
Range %96-108
1:8Average %95
Range %88-100
Recovery
The recovery of human LILRA3 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9789-104
EDTA plasma (n=4)9690-100
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/mlOD1OD2AverageCorrected
102.197 2.099 2.148 2.056
51.349 1.425 1.387 1.295
2.50.904 0.926 0.915 0.823
1.250.577 0.603 0.590 0.498
0.6250.410 0.404 0.407 0.315
0.3120.255 0.254 0.255 0.163
0.1560.178 0.174 0.176 0.084
00.092 0.091 0.092  
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 5-7 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Data

Function Acts as soluble receptor for class I MHC antigens. Binds both classical and non-classical HLA class I molecules but with reduced affinities compared to LILRB1 or LILRB2. Binds with high affinity to the surface of monocytes, leading to abolish LPS-induced TNF-alpha production by monocytes.
Gene References into Functions
  1. Mutations in the genes glucokinase regulatory protein (GCKR), RNase L (RNASEL), leukocyte immunoglobulin-like receptor 3 (LILRA3), and dynein axonemal heavy chain 10 (DNAH10) segregated with elevated HDLc levels in families, while no mutations associated with low HDLc. PMID: 24891332
  2. The homozygous LILRA3 deletion is associated with a higher susceptibility for HIV disease and with a faster disease progression. PMID: 27755104
  3. Letter: LILRA3 gene deletion is not involved in the giant cell arteritis and systemic sclerosis predisposition in Spanish patients. PMID: 27462831
  4. LILRA3 significantly reversed Nogo-66-mediated inhibition of neurite outgrowth and promoted synapse formation in primary cortical neurons through regulation of the ERK/MEK pathway. PMID: 26826187
  5. Experiments point towards a beneficial role for LILRA3 in virus infections, especially in ssRNA viruses, like HIV, that engage TLR8; however, the potentially beneficial role of LILRA3 is abrogated during a HIV infection. PMID: 26969150
  6. LILRA3 gene deletion was not associated with Multiple Sclerosis susceptibility and did not affect the age of disease onset, clinical subtype or disease severity. PMID: 26871720
  7. Evidence showed lack of significant association between LILRA3 deletion and multiple sclerosis pathogenesis. [meta-analysis] PMID: 26274821
  8. LILRA3 is a new susceptibility factor for systemic lupus erythematosus (SLE) and primary Sjogren's syndrome (pSS). It predisposes to certain phenotypes such as leucopenia, thrombocytopenia, autoantibody positivity and increased disease activity. PMID: 24906639
  9. The current study was conducted to investigate the association of rs103294 of LILRA3 with benign prostatic hyperplasia risk. PMID: 23615473
  10. ILT6 deletion polymorphism does not appear to be a lupus susceptibility gene in South Indian Tamils, but may behave as a genetic modifier of autoantibody phenotype by influencing the production of anti-Ro60 and anti-Ro52 autoantibodies PMID: 24899637
  11. LILRA3 is an immunostimulatory molecule, whose deficiency is associated with higher frequency of B-non-Hodgkin's lymphoma. PMID: 24363809
  12. functional LILRA3 is a novel genetic risk factor for rheumatoid arthritis (RA), especially in males. It appears to highly predispose to ACPA-positive RA and confers an increased risk of disease severity in patients with early RA. PMID: 24757135
  13. Data did not indicate any association of LILRA3 deletion with multiple sclerosis (MS) susceptibility, however, patients negative for the deletion may begin to suffer from MS significantly earlier than patients who are positive. PMID: 23238213
  14. LILRA1 and LILRA3 generally display a greater binding preference for binding to HLA-C free heavy chain, particularly following removal of beta2-microglobulin by acid treatment. PMID: 21270408
  15. These results suggest that LILRA3 may play a role in chronic inflammatory conditions such as rheumatoid arthritis. PMID: 20595277
  16. A deletion of LILRA3 gene was found in a minority of British population PMID: 12651072
  17. Six alleles characterised, of which four will encode unique peptides, one of which is likely to directly influence ligand binding. PMID: 12750859
  18. Multiple sclerosis associates with LILRA3 deletion. PMID: 19421224
  19. ILT6 deficiency may be a genetic risk factor for Sjogren's syndrome. PMID: 19790059

Show More

Hide All

Subcellular Location Secreted
Tissue Specificity Detected in B-cells, and at lower levels in natural killer (NK) cells. Detected in peripheral blood monocytes and lung.
Database Links

HGNC: 6604

OMIM: 604818

KEGG: hsa:11026

STRING: 9606.ENSP00000251390

UniGene: Hs.113277

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1